Frank Hensel

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

dualyx NV focuses on the discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases. We aim to create long-lasting treatments for patients with a high unmet medical need.

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1.  Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).  Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

Mecuris is a provider of digital services for the medical aids industry. Our goal is to offer medical professionals and certified prosthetist orthotists (CPO) the possibility to create individual orthoses online in a cost- and time-saving way. To this end, Mecuris translates traditional craftsmanship into digital tools and workflows and makes them available in its web-based digital workshop - the Mecuris Solution Platform. This easy-to-use platform makes it possible to combine classic craftsmanship with the benefits of digitization. The platform can be used intuitively, which means that the CPO does not need to have prior knowledge of 3D technologies. From posture correction of a user scan to orthosis modeling and configuration: all processes for creating an orthosis can be carried out digitally, either in individual steps or as a whole. Afterwards, the finished item can be manufactured in the preferred milling or 3D printing facility. The individual components of the digital services are constantly being developed further and offered in a flexible freemium plan. This means that medical supply stores of any size can make a quick and economic start on digitization. Using the digital tools of Mecuris will lead to a 100% customised fit and cuts production times by 75% for the medical practitioners and patients. Check it out! Mecuris has a young minded & international team with a central office in the heart of Munich (currently @HomeOffice). With our work we can directly influence the improvement of the quality of life of users (patients). You are looking for a new challenging position? More than just a 9-5 job? Do not hesitate and apply right here: mecuris.com/jobs Mecuris. You Create. Impressum: https://www.mecuris.com/impressum-datenschutz

Scipio Bioscience, a Paris-based biotechnology company, provides novel sample preparation solutions for single-cell studies in the form of easy-to-use benchtop kits and intuitive, cloud-based software. Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. The initial target of Scipio Bioscience is to provide sample preparation for single-cell transcriptomics freed of the substantial investment and running costs of existing technologies, while attaining the flexibility and scalability required in state-of-the-art research. The blooming applications in single-cell transcriptomics have revealed the importance of characterizing the diversity of cell profiles in normal tissues and cancerous tumors. For optimal results, numbers of cells in the range of thousands must be analyzed simultaneously by RNA-sequencing procedures. The costs and constraints of available methods for sample preparation have hampered widespread adoption of this approach. Scipio Bioscience overcomes these obstacles by providing a test-tube solution readily accessible to laboratories in all fields of biological research. The first outcome of this technology was the commercial release of the Asteria™ Single-cell RNA-seq Kit and its companion data analysis software Cytonaut™ in May 2022. Able to analyze 10,000 input cells in a single-tube, the kit bypasses the use of microfluidics or plate in favor of a simple, accessible protocol that is easier on cells and enables a stable stopping point 2 hours in. The resulting sequencing data can be analyzed with Cytonaut™, a cloud-based software that covers the entire 3’ scRNA-seq data analysis chain and emphasizes on the ease-of-use for biologists and bioinformaticians alike. Scipio bioscience is housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany. Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.

We are Computomics - a biotech company enabling customers to reap the benefits of our advanced machine learning algorithms. By applying AI to genetics, phenotype, microbiome, and environmental datasets, we unlock the diversity of biological life. Computomics is a team of world-leading experts in machine learning, plant research and bioinformatics. In over 180 projects, we enabled our customers to make data-driven decisions and thereby accelerate sustainable agricultural development that can feed the world. Our advanced machine learning methods enable rapid understanding of genomic data for plant breeding, agricultural, biotech, and microbiome researchers. Computomics has its headquarters in Tübingen, Germany.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

dualyx NV focuses on the discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases. We aim to create long-lasting treatments for patients with a high unmet medical need.

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.